Summary Vascular endothelial growth factor (VEGF) has been identified as an important factor for tumour angiogenesis, which is essential for the growth, invasion and metastasis of solid tumours. Significantly increased VEGF level from the primary tumour to the metastatic lesion of ovarian cancers was found in 8 of 30 cases. The 24-month survival rate of the patients with significantly increased VEGF level was extremely poor (0/8 = 0%) in comparison with that of patients with no change in the level (15/22 = 68%) from the primary tumour to the metastatic lesion. This indicates that VEGF may contribute to the advancement of metastatic lesions, and that VEGF level in metastatic lesions may be a prognostic indicator.
Neovascularization is essential for growth of and nutrition to solid tumours greater than 2 mm in diameter (Folkman, 1985) . Among angiogenic factors, VEGF was initially recognized as a vascular permeability factor (34-42 kDa) that induced tumour ascites (Senger et al, 1983) . Afterward, VEGF was identified as a vascular permeability factor that is active in increasing blood vessel permeability, endothelial cell growth and angiogenesis (Leung et al, 1989) . Similarly, it was described as having a direct-acting mitogen specific for vascular endothelial cells (Keck et al, 1989) . VEGF is expressed in tissues with rapid vascular endothelial turnover, which are reproductive organs such as ovary, uterus and placenta, and in tumours (Garrido et al, 1993; Li et al, 1994; Jackson et al, 1994) . The level of VEGF correlates with microvessel density, but not with worsened patient prognosis in uterine cervical cancers (Fujimoto et al, 1999a) . The expression of VEGF was down-regulated with advancement of uterine endometrial cancers lacking sex steroidal dependency (Fujimoto et al, 1998a (Fujimoto et al, , 1999b . In ovarian cancers, the expression of VEGF has been well demonstrated (Boocock et al, 1995; Abu-Jawdeh et al, 1996; Paley et al, 1997) , and since the elevation of VEGF in ovarian cancers correlates with worsened patient prognosis, VEGF in the primary tumour of ovarian cancers is recognized as a prognostic indicator (Fujimoto et al, 1998b) . On the other hand, although the presence of peritoneal metastasis in ovarian cancers is critical to patient prognosis (Eisenkop et al, 1993; Kapp et al, 1999) , there is as yet no prognostic indicator for peritoneal metastasis-positive patients. This status prompted us to investigate the clinical significance of VEGF expression in peritoneal metastatic tumours of ovarian cancers.
MATERIALS AND METHODS

Patients
Informed consent for the following studies were obtained from all patients and the Research Committee for Human Subjects, Gifu University School of Medicine. Thirty patients ranging from 32 to 74 years of age underwent operation for ovarian cancer stage III at the Department of Obstetries and Gynecology, Gifu University School of Medicine between January 1995 and January 1998 ( Table 1) . None of the patients had received any preoperative therapy. A part of the tissues of ovarian cancers (the peritoneal metastatic lesion and the corresponding primary tumour) was obtained immediately after the resection and snap-frozen in liquid nitrogen to determine the levels of VEGF, and a neighbouring part of the tissues was submitted for histopathological study. The histological types and clinical stages were determined by International Federation of Obstetrics and Gynecology (FIGO) classification (FIGO News, 1989) . Twenty-four-month survival rates were calculated for the 30 patients, all of whom underwent curative resection for ovarian cancer that achieved macroscopically disease-free status, and analyzed using the Kaplan-Meier method.
Immunohistochemistry
Four-µm sections were cut from formalin-fixed paraffinembedded tissue with a microtome and dried overnight at 37˚C on a silanized-slide (Dako, Carpinteria, CA, USA). Samples were deparaffinized in xylene at room temperature for 80 min and washed with a graded ethanol/water mixture and then with distilled water. The samples for VEGF were soaked in a citrate buffer and then microwaved at 100˚C for 10 min. The protocol for DAKO LSAB2 Kit, Peroxidase (Dako) was followed for each sample. In the described procedure, rabbit anti-human VEGF antigen VEGF(147) (200 µg/ml, Santa Cruz Biotechnology, Santa Cruz, CA, USA) as the first antibody was used at a dilution of 1:100. The antibody against a peptide corresponding to amino acids 1-147 of VEGF can detect all isoforms of VEGF (wild type VEGF 206 , VEGF 189 , VEGF 165 , and VEGF 121 ). The addition of the first antibody was omitted in the protocol for negative controls.
Enzyme immunoassay for determination of human VEGF antigen
All steps were carried out at 4˚C. Tissues (wet weight: 10-20 mg) were homogenized in HG buffer (5 mM Tris-HCl, pH 7.4, 5 mM NaCl, 1 mM CaCl 2 , 2 mM ethyleneglycol-bis-[β-aminoethyl ether]-N,N,N′, N′-tetraacetic acid, 1 mM MgCl 2 , 2 mM dithiothreitol, 25 µg/ml aprotinin, and 25 µg/ml leupeptin) with a Polytron homogenizer (Kinematics, Luzern, Switzerland). This suspension was centrifuged in a microfuge at 12 000 rpm for 3 min to remove the nuclear pellet. The protein concentration of samples was measured by the method of Bradford to standardize VEGF antigen levels (Bradford, 1976) .
VEGF antigen levels in the samples were determined by a sandwich enzyme immunoassay using a Human VEGF Assay Kit-IBL (Immuno Biological Laboratories, Gunma, Japan). The levels of VEGF were standardized with the corresponding cellular protein concentrations.
Statistics
The levels of VEGF were measured from three parts of the same tissue of each primary tumour and metastatic lesion in triplicate (9 determinations each; 18 determinations for each case). The ttest for two independent samples was used in a one-tail manner to compare the nine determinations for each primary tumour against the nine determinations for each metastatic lesion (30 independent t-tests). Survival curves were calculated using the Kaplan-Meier method, and analyzed by the log-rank test. Differences were considered significant when P was less than 0.05.
RESULTS
Immunohistochemical staining for VEGF (n = 30) was carried out to study VEGF localization and the intensity of staining in the peritoneal metastatic lesion and the corresponding primary tumour. As shown in Figure 1 , positive staining is seen dominantly in the cytoplasm of the cancer cells, and faintly in interstitial cells. There was no case of decreased intensity from the primary tumour to the metastatic lesion. Obviously increased intensity from the primary tumour to the metastatic lesion was found in 8 of 30 cases of ovarian cancers.
Enzyme immunoassay for VEGF was carried out to study VEGF level in the peritoneal metastatic lesion and the corresponding primary tumour. As shown in Figure 2 , there was no case of decreased VEGF level from the primary tumour to the metastatic lesion. Significantly, (P < 0.05) increased VEGF level from the primary tumour to the metastatic lesion was found in 8 of 30 cases, the same cases that showed increased intensity of immunohistochemical staining for VEGF. Ms, mesentery; Ly, pelvic lymph nodes G1, well-differentiated; G2, moderately differentiated, G3, poorly differentiated; Ad, adenocarcinoma; cyAd, cystadenocarcinoma; ppcyAd, papillary cystadenocarcinoma; Increased, cases with significantly increased VEGF level from the primary tumour to the peritoneal metastatic lesion; NC, cases with no change in VEGF level from the primary tumour to the peritoneal metastatic lesion.
We analysed the prognosis of the 30 patients who underwent curative resection and whose 24-month survival rates were calculated. As shown in Figure 3 , the prognosis of patients with significantly increased VEGF level was significantly (P < 0.05) poor (0.8 = 0%) compared to that of patients with no change in the level (15/22 = 68%) from the primary tumour to the peritoneal metastatic lesion.
DISCUSSION
Newly developed capillary network formation from the original vessel is designated as neovascularization. Generally, turnover of capillary endothelial cells is extremely slow to the order of months or years in physiological neovascularization, while the turnover in ovary and uterine endometrium is altered to a rapid state within the ovarian cycle. The turnover with malignant transformation becomes rapid, which might contribute to the acceleration of tumour growth (Denekamp, 1984) .
Among angiogenic factors, VEGF has been evaluated as an important factor for tumour angiogenesis, which is essential for the growth of solid tumours. Generally speaking, VEGF secreted from tumours contributes to tumour growth not via an autocrine pathway to tumour cells, but via a paracrine pathway to surrounding microvessels (Berkman et al, 1993) . The elevation of VEGF in ovarian cancers correlates with worsened patient prognosis (Fujimoto et al, 1998b) . On the other hand, KDR, a receptor Figure 2 Levels of VEGF in peritoneal metastatic lesion and corresponding primary tumor of ovarian cancers. The levels of VEGF were determined by a sandwich enzyme immunoassay using a Human VEGF Assay Kit-IBL (Immuno Biological Laboratories, Gunma, Japan). Each result is the mean of 9 determinations. Number in, living case; number in q, deceased case.
* P < 0.05 vs the corresponding primary tumour of VEGF, is expressed by some ovarian cancer cells that co-express VEGF (Boocock et al, 1995) . Co-expression of VEGF and KDR by tumour cells in ovarian cancer raises the possibility of autocrine stimulation (Boocock et al, 1995) . Furthermore, it facilitates metastasis via neovascularization (Warren et al, 1995) . Although the presence of peritoneal abdominal metastasis is critical to patient prognosis, there is as yet no prognostic indicator for peritoneal metastasis-positive patients in ovarian cancers. In the present study, it was demonstrated that the prognosis of patients with increased VEGF level from the primary tumour to the peritoneal metastatic lesion was extremely poor in comparison with that of patients with no change in the level. Thus, VEGF may contribute to the advancement of metastatic lesions, and VEGF level in metastatic lesions may be a prognostic indicator. This indicates that anti-VEGF and VEGF receptor antibodies (Borgstrom et al, 1996; Yuan et al, 1996; Zhu et al, 1998; Prewett et al, 1999 ) might be effective against advanced ovarian cancers, especially the cases with increased VEGF level from the primary tumour to the metastatic lesion, apart from a direct anti-tumoural effect on cancer cells.
